This is consistent with our previous findings using a pharmacological approach where STZ-diabetic mice were treated with a prototype inhibitor of CDA1, CHA-061, for 5 weeks during weeks 6–10 after diabetes induction [35]. Here, TSPYL2 is linked to diabetes mellitus.